High sarcopenia levels appear to be negatively associated with overall survival in male patients with esophageal carcinoma treated with upfront chemoradiotherapy.
Use of a 30 mm hydrostatic balloon dilator (EsoFLIP-330) was safe in treating patients with esophageal motility disorders and was most effective in those with achalasia.
Patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) following atrial fibrillation were more likely to develop gastrointestinal bleeding and malignancies.
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Dupilumab was associated with clinical and anatomic improvements in patients with eosinophilic esophagitis, according to results from a pivotal phase 3 study.
An international, multicenter study was conducted to assess the long-term safety and efficacy of an experimental monoclonal antibody against interleukin-13 in patients with eosinophilic esophagitis.
Low expression of the HPV-related marker cyclin D1 appears to be an independent prognostic marker in Barrett high-grade dysplasia and esophageal adenocarcinoma.
Patients with Barrett’s esophagus undergoing endoscopic eradication therapy demonstrated a low rate of recurrence of intestinal metaplasia and dysplasia after complete eradication of intestinal metaplasia.
An abnormal glucose tolerance test to screen for potential dumping syndrome around 3 months of age should be considered in infants born with esophageal atresia.
A risk prediction model consisting of 8 independent diagnostics can provide potential insight into a patient’s risk for Barrett’s esophagus before endoscopy, according to a study in published in Lancet Digital Health.
Gastroenterologists who are members of an EoE consortia are much more likely to routinely screen for adrenal insufficiency in children with eosinophilic esophagitis who are being treated with topical corticosteroids.
